Brief: Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis
23/09/2024 14:17
Sept 23 (Reuters) - Aileron Therapeutics Inc ALRN.O :
* AILERON THERAPEUTICS COMPLETES ENROLLMENT IN COHORT 2 OF
THE
ONGOING PHASE 1B CLINICAL TRIAL EVALUATING LTI-03 IN IDIOPATHIC
PULMONARY FIBROSIS (IPF)
* AILERON THERAPEUTICS INC - COHORT 2 TO EVALUATE HIGH-DOSE
LTI-03
(5 MG BID)
Source text for Eikon: ID:nPnbMRt7Ba
Further company coverage: ALRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rein Therapeutics
See all newsBrief: Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis
Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Rein Therapeutics Q2 net loss narrows on lower R&D spending
Rein Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering